COVID-associated non-vasculitic thrombotic retiform purpura of the face and extremities: A case report.
Connor M Bunch, Nuha Zackariya, Anthony V Thomas, Jack H Langford, Michael Aboukhaled, Samuel J Thomas, Aida Ansari, Shivani S Patel, Hallie Buckner, Joseph B Miller and 9 more
Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
St. Joseph Regional Medical Center · USHenry Ford Hospital · USIndiana University South Bend · USMishawaka-Penn-Harris Public Library · USBeacon Health System · USMarian University - Indiana · USSouth Bend Medical Foundation · US
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
SARS-CoV-2 infection can manifest many rashes. However, thrombotic retiform purpura rarely occurs during COVID-19 illness. Aggressive anti-COVID-19 therapy with a high-dose steroid regimen led to rapid recovery. This immunothrombotic phenomenon likely represents a poor type 1 interferon response and complement activation on the endothelial surface in response to acute infection.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
COVID-associated non-vasculitic thrombotic retiform purpura of the face and extremities: A case report. · full record | OpenQuestion